These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7843696)

  • 1. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial.
    Kasahara A; Hayashi N; Hiramatsu N; Oshita M; Hagiwara H; Katayama K; Kato M; Masuzawa M; Yoshihara H; Kishida Y
    Hepatology; 1995 Feb; 21(2):291-7. PubMed ID: 7843696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
    J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphoblastoid alpha-interferon for chronic hepatitis C: a randomized controlled study.
    Castilla A; Camps-Bansell J; Civeira MP; Prieto J
    Am J Gastroenterol; 1993 Feb; 88(2):233-9. PubMed ID: 8424427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of hepatitis C: re-treatment with alpha interferon.
    Alberti A; Chemello L; Noventa F; Cavalletto L; De Salvo G
    Hepatology; 1997 Sep; 26(3 Suppl 1):137S-142S. PubMed ID: 9305679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management.
    Roffi L; Mels GC; Antonelli G; Bellati G; Panizzuti F; Piperno A; Pozzi M; Ravizza D; Angeli G; Dianzani F
    Hepatology; 1995 Mar; 21(3):645-9. PubMed ID: 7875661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
    Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
    Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.
    Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K
    Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial.
    Chung YH; Song BC; Lee GC; Shin JW; Ryu SH; Jung SA; Yoo K; Lee HC; Lee YS; Suh DJ
    Eur J Gastroenterol Hepatol; 2003 May; 15(5):489-93. PubMed ID: 12702905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic hepatitis C with interferon alpha: long-term follow-up and prognostic relevance of HCV genotypes.
    Hopf U; Berg T; König V; Küther S; Heuft HG; Lobeck H
    J Hepatol; 1996; 24(2 Suppl):67-73. PubMed ID: 8836892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
    Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
    J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(5):319-24. PubMed ID: 8588128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
    Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study for relapse cases of chronic hepatitis C treated with interferon (IFN) and approach to more successful re-treatment of IFN].
    Iwabuchi S; Yoshida H; Fukui S
    Nihon Rinsho; 1994 Jul; 52(7):1810-6. PubMed ID: 7521423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.